erbB-2 and response to doxorubicin in patients with axillary lymph node- positive, hormone receptor-negative breast cancer

Journal of the National Cancer Institute

Volumn 90, Issue 18, 1998, Pages 1361-1370

  Paik, Soonmyung ^a,b   Bryant, John ^c   Park, Chanheun ^d   Fisher, Bernard ^d   Tan Chiu, Elizabeth ^d   Hyams, David ^d   Fisher, Edwin R ^d   Lippman, Marc E ^e   Wickerham, D Lawrence ^d   Wolmark, Norman ^d  

^a NSABP Foundation Inc   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MELPHALAN; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE NEU; ORAL DRUG ADMINISTRATION; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0032538040     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.18.1361     Document Type: Article

References (22)

1. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88: 1456-66.
2. Gusterson BA. The changing role of pathologist in the prediction of tumor behavior and response to treatment. In: Dickson RB, Lippman ME, editors. Drug and hormonal resistance in breast cancer. New York: Ellis Horwood: 1995. p. 39-53.
3. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer [published erratum appears in N Engl J Med 1994;331: 211]. N Engl J Med 1994;330: 1260-6.
4. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56.
5. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
6. Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver KL, Hurd SD, et al. p185c-erbB-2 signalling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994; 54:3758-65.
7. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 1997;11(3 Suppl 2):43-8.
8. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, et al. Elevated serum c-erhB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35.
9. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II. node-positive breast carcinoma [published erratum appears in N Engl J Med 1994;331:139]. N Engl J Med 1994;330:1253-9.
10. Jarvinen TA, Kononen J, Pelto-Huikko M, Isola J. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 1996;148:2073-82.
11. Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N, et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 1989;7:572-82.
12. Paik S, King CR, Simpson S, Lippman ME. Quantification of erbB-2/neu levels in tissue. Methods Enzymol 1991;198:290-300.
13. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993;8:933-8.
14. Harris AL, Carmichael J. Topoisomerase inhibitors and multiple drug resistance mechanisms in human breast cancer. In: Dickson RB, Lippman ME, editors. Drug and hormonal resistance in breast cancer. New York: Ellis Horwood; 1995. p. 303-22.
15. Keith WN, Douglas F, Wishart GC, McCallum HM, Geroge WD, Kaye SB, et al. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer 1993;10:1469-75.
16. Tripathy D, Henderson IC. Clinical resistance in breast cancer. In: Dickson RB, Lippman ME, editors. Drug and hormonal resistance in breast cancer. New York: Ellis Horwood: 1995. p. 3-20.
17. Berry DA, Thor A, Cirrincione C, Edgerton S, Muss H, Marks J, et al. Scientific inference and predictions: multiplicities and convincing stories: a case study in breast cancer therapy. In: Bernardo JM, Berger JO, Dawid AP, Smith AF, editors. Bayesian statistics, vol. 5. Oxford (U.K.): Oxford University Press: 1996. p. 45-67.
18. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, et al. Correlations between intrinsic chemoresistance and HER-2/neu gene expression. p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 1996;56:206-9.
19. Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst 1995;87:682-4.
20. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, et al. HER2/Neu and the Ets transcription activator PEA3 are coordinately up-regulated in human breast cancer. Oncogene 1997;15:1513-25.
21. Fisher B, Brown AM, Dimitrov NV, Poison R, Redmond C, Margolese RG, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-96.
22. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989:244:707-12.